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Both high-sucrose diet and dexamethasone (D) treatment increase plasma insulin and glucose levels and induce 
insulin resistance. We showed in a previous work (Franco-Colin, et al. Metabolism 2000; 49:1289-1294) that 
combining both protocols for 7 weeks induced less body weight gain in treated rats without affecting mean daily 
food intake. Since such an effect may be explained by an increase in caloric expenditure, possibly due to 
activation of the sympathetic nervous system by sucrose ingestion, in this work, and using 10% sucrose in the 
drinking water, male Wistar rats were divided into 4 groups. Two groups were sympathectomized using 
guanethidine (Gu) treatment for 3 weeks. One of these groups of rats received D in the drinking water. Of the 2 
groups not receiving Gu, one was the control (C) and the other received D. After 8 weeks a glucose tolerance test 
was done. The rats were sacrificed and liver triglyceride (TG), perifemoral muscle lipid, and norepinephrine 
(NE) levels in the liver spleen, pancreas, and heart were determined. Gu-treated rats (Gu and Gu+D groups) 
showed less than 10% NE concentration compared to C and D rats, less daily caloric intake and body-weight 
gain, more sucrose intake, and better glucose tolerance. The area under the curve after glucose administration 
correlated significantly with the mean body weight gain of the rats, except for D group. Groups D (D and Gu+D) 
also showed less caloric intake and body-weight gain but higher liver weight and TG concentration and lower 
peripheral muscle mass. The combination of Gu+D treatments showed some peculiar results: negative body 
weight gain, a fatty liver, and low muscle mass. Though the glucose tolerance test had the worst results for the D 
group, it showed the best results in the Gu+D group. There were significant interactions for Guan X Dex by two-
way ANOVA test for the area under the curve in the glucose tolerance test, muscle mass, and muscle lipids. The 
results suggest that dexamethasone catabolic effect is not caused by sympathetic activation. 
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1.  INTRODUCTION 
Weight gain or loss in otherwise healthy humans 
and animals is because of an imbalance between 
caloric intake and caloric expenditure. The first term 
is represented by the quantity of macronutrients 
ingested during a time interval (days, weeks, etc) 
taking into account that each macronutrient has a 
specific caloric value. Caloric expenditure is more 
difficult to estimate and is usually measured using 
indirect calorimetry. 
Glucocorticoids are involved in the control of 
energy metabolism and body weight. Long-term 
administration of dexamethasone (D) in low doses in 
the drinking water of rats (3 – 4 μg/day) reduced 
weight gain without affecting food intake, suggesting 
an increase in caloric expenditure [1,2].  
Feeding a sucrose diet induces some effects 
similar to those of D administration, such as the 
increase in insulin levels and resistance [3,4] and in 
plasma glucose levels [5]. The common mechanism of 
the action of glucose and D on glucose metabolism 
seems to be the sensitization of pancreatic β-cells to 
glucose-induced insulin secretion [6,7]. In a previous 
work when we used both D treatment and high-
sucrose diet in rats, the stronger effect on fat 
accumulation relative to body weight was seen only 
after the combination of both treatments [2]. 
Another factor clearly involved in the control of 
metabolism and energy balance is the activity of the 
sympathoadrenal system. Both epinephrine (E) and 
norepinephrine (NE) are assumed to be implicated in 
the control of feeding [8] and of body weight [9], 
along with their well-known effect on plasma glucose 
and free fatty acid levels that results from their 
actions on the hepatic and adipose tissue. In spite of 
the important role played by the sympathetic nervous 
system in the cardiovascular, renal, respiratory, and 
metabolic functions, chronic sympathectomy, 
induced experimentally by guanethidine (Gu) 
treatment [10], produces only small alterations when 
administered either to neonatal or adult rats. Gu 
treatment has been reported to have no effect on body 
weight [11] or just to lower it slightly [12,13]. Caloric 
intake is slightly reduced [11,14]. Recently we showed 
that neonatal rats treated with Gu show, as adults, a 
higher hypophagic response to intraperitoneal 
catecholamine administration, a lower resting oxygen 
consumption, and a higher respiratory quotient at 
rest, suggesting a lower rate of  lipid use [15]. While Int. J. Biol. Sci. 2006, 2  18
both high-sucrose diet and D administration induces 
similar changes in glucose and lipid metabolism, the 
experimental manipulation of these two factors has 
opposite effects on the sympathetic nervous system 
activity: sucrose ingestion stimulates it [16] whereas 
D has been reported to suppress it [17].  
Because of our interest in the metabolic effects of 
sympathectomy [15] the aim of the present work was 
to assess in adult rats the effects of D on a 
background of a high-sucrose diet, on food intake, 
body weight, glucose tolerance, and lipid 
accumulation in the liver and muscle in rats treated 
with Gu. It was hypothesized that the poor food 
efficiency shown by D-treated rats [1,2] might be 
caused by an increase in energy expenditure perhaps 
due to an increase in sympathetic activity. 
2.  MATERIAL AND METHODS 
Animals and diet 
Twenty-eight male Wistar rats (377 ± 7 g; 6 - 8 
m o n t h s  o l d )  w e r e  h o u s e d  i n  i n d i v i d u a l  c a g e s  i n  a  
temperature-controlled room (23° ± 1°C) with a 12 h 
light/12 h dark cycle. Powdered Rodent Lab Chow 
5001 and 10% sucrose in tap water were available ad 
libitum. At the start of the experiment, the rats were 
divided into 4 groups, each having 7 rats of similar 
mean body weight. 
Treatments 
After one week, 2 groups of rats received 
guanethidine (Guanethidine monosulfate, Sigma 
Chem., St Louis, MO) 50 mg/kg intraperitoneally (ip) 
three times a week for 3 weeks. After two weeks of 
guanethidine (Gu) treatment, 2 groups of animals, 
one having received Gu and another without Gu, 
started to drink water containing, beside sucrose, 
dexamethasone (Decadron, Lab. Merck Sharp & 
Dohme, Mexico) in doses calculated, according to the 
water intake of each treated rat,  to represent 
approximately 2.2 μg dexamethasone (D) per rat per 
day. Oral D administration was continued until rats 
were sacrificed. This yielded 4 experimental groups: 
control (C), guanethidine (Gu), dexamethasone (D), 
and Gu +D.  
Measurements 
Food and water intake were measured daily and 
body weight weekly for 7 weeks, one week before the 
start of the Gu treatment, the 3 weeks of Gu treatment 
and the 4 weeks of D treatment, with one week 
overlap of  the two treatments. Water intake 
measurements allowed the determination of sugar 
intake. Total caloric intake expressed as kJ/day was 
calculated by summing the sucrose ingestion 
(estimated to be 4 Cal = 16.74 kJ) and the chow intake 
(3.96 Cal = 16.57 kJ). After these 56 days, and 
continuing D oral administration, glucose tolerance 
was determined in the rats that had fasted overnight. 
Blood was obtained from the tail tip and whole-blood 
glucose concentrations were measured using an 
enzymatic kit (Farmaceuticos Lakeside, Mexico) 
before and 30, 60, and 120 min after ip injection of  3.6 
g/kg (20 mmol/kg) of glucose. Finally, 7 to 10 days 
later and after an overnight fast the rats were 
anesthetized  with 60 mg/kg sodium pentobarbital 
(Anestesal, SmithKline Beecham, Farmaceutica, 
Mexico), their abdomens were opened, their liver was 
removed and weighed, and then frozen for further 
triglyceride determinations. A sample of liver, 
pancreas, spleen, and heart ventricle was also 
immediately removed, homogenized in ice-cold 0.4 N 
perchloric acid, centrifuged, and kept at -20°C for 
catecholamine analysis. The perifemoral muscles of 
one leg were also dissected and frozen for further 
lipid determinations. Liver triglycerides were 
determined using a kit from Sigma Chem., St. Louis, 
MO. The total lipids in dried samples of muscle were 
obtained by extraction in a Soxhlet Extractor (Kimax, 
Mexico) with petroleum ether. Catecholamines were 
extracted, after thawing of tissue samples, by 
adsorption on acid-washed alumina in Tris buffer 
(pH 8.6) containing EDTA, washed with deionized 
water several times, and eluted in 200 μL 0.1 N 
perchloric acid. Norepinephrine (NE) and 
epinephrine (E) concentrations were measured using 
high-performance liquid chromatography with 
electrochemical detection (ESA Coulochem II; 
Bedford, MA) by using a degassed mobile phase in an 
isocratic 0.6 mL/min flow, with 3,4-
dihydroxybenzylamine added as an internal standard 
[15,18]. 
Statistics 
The data were analyzed by two-way 
(Guanethidine X Dexamethasone) and one-way 
analysis of variance (ANOVA). Results are expressed 
as mean ± SEM. Linear regression was calculated 
between the glycemia AUC and the mean daily body 
weight gain. The level of significance was set at P < 
0.05.  
3.  RESULTS 
Norepinephrine levels were drastically reduced 
by Gu treatment in the 4 organs (Table 1).  
Table 1. Norepinephrine levels (ng/g) in liver, spleen, 
pancreas, and heart in the four groups of rats 
Treatments/organ  Liver Spleen Pancreas Heart 
 
Control 
 
48.3±3.5ª 
 
1001.0±165.8a 
 
440.5±114.4a 
 
430.9±53.1a 
 
Guanethidine 
 
3.9±1.1b 
 
7.2±1.9b 
 
45.8±24.6b 
 
12.2±2.8b 
 
Dexamethasone 
 
57.5±6.6a 
 
880.6±144.0a 
 
586.3±54.1a 
 
649.7±124.4a 
 
Guan+Dex 
 
4.2±1.3b 
 
28.4±15.3b 
 
16.0±6.0b 
 
20.0±11.0b 
ANOVA(F) 
Guanethidine 
12** 67**  74**  38** 
** P < 0.01 by two-way ANOVA. Within a column, values bearing the 
same letter are not significantly different by one-way ANOVA.  
 
Epinephrine levels in the unsympathectomized 
groups of rats were much lower than those of NE and 
Gu reduced them only in the heart: 5.7 ± 1 ng/g vs 9.7 
± 1.2 ng/g (F = 7.5, P  < 0.02). Dexamethasone Int. J. Biol. Sci. 2006, 2  19
treatment did not affect catecholamine 
concentrations. 
Total caloric intake (kJ/day), percentage of 
sucrose intake, and body weight gain (g/day) were 
calculated for 7 weeks for the control group (C), 6 
weeks for the Gu-treated rats (groups Gu and Gu+D) 
and 4 weeks for the group that received only 
dexamethasone (group D). Table 2 shows less food 
intake for the three treated groups, without 
significant differences among them. Relative sucrose 
intake was higher in Gu+D rats. Body-weight gain 
was much more affected in both groups receiving D 
treatment. All three variables were affected more by 
the combination of sympathectomy with D treatment. 
Table 2. Total caloric intake, percentage of sucrose intake, 
and body weight gain in the four groups of rats.  
Treatments Total  caloric 
intake 
 (kJ/day) 
Sucrose 
caloric 
intake (%) 
Body weight 
gain 
g/day 
 
Control 
 
 
446.0±14.4a 
 
48.0±1.3a 
 
1.26±0.16a 
Guanethidine 
 
390.8±9.5b 51.6±2.6ab 0.87±0.15a 
Dexametasone 404.2±13.7b 50.7±1.4a 0.20±0.13b 
 
Guan + Dex 
 
370.3±17.6b 
 
56.8±1.4b 
 
-0.37±0.22b 
 
ANOVA (F) 
    
 
Guanethidine 
 
15.8** 
 
7.5* 
 
12.3** 
 
Dexamethasone 
 
7.7** 
 
4.8* 
 
70.8** 
 
Guan X Dex 
 
0.9 
 
0.5 
 
0.5 
*P < 0.05; 
** P < 0.01 by two-way ANOVA. Within a column, values 
bearing the same letter are not significantly different by one-way 
ANOVA.  
 
Figure 1 shows the evolution of blood glucose 
after 3.6 mg/kg glucose ip. Glucose tolerance was 
significantly improved in the sympathectomized 
groups and the D group showed the worst tolerance. 
Excepting the D group, there is a significant 
correlation (P < 0.02) between glucose AUC after 
glucose administration and body-weight gain (Fig. 2). 
Table 3 shows the relative liver weight, the 
relative content of triglycerides in the liver and lipids 
in the perifemoral muscles, and the wet weight of the 
muscle. Relative liver weight and liver triglycerides 
were significantly higher in both groups of D-treated 
rats, whereas lipids in muscle were higher only in the 
Gu+D group. The significant interaction between Gu 
and D treatment in this case shows that only their 
combination increased muscle lipids under these 
particular conditions. Similar differences between 
groups are shown by the perifemoral muscle mass.  
Figure 1. Evolution of whole-blood glucose before and 
after the intraperitoneal administration of 3.6 g glucose per 
kg in control (C), dexamethasone (D)-, guanethidine (Gu)-, 
and guanethidine plus dexamethasone (Gu+D)-treated rats. 
Two-way ANOVA results for Area Under the Curve 
(AUC) are inserted. Values bearing the same letter for the 
glycemic level at each time interval and for AUC values 
(mean glycemia in 120 min) are not significantly different 
by one-way ANOVA. 
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Figure. 2. Individual correlation for glycemia AUC and daily body weight gain. (―) Linear regression for all rats (r = 0.29, 
not significant; (---) Linear regression without D group (r = 0.64, P < 0.02). 
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Table 3. Relative weight and triglyceride content of liver, relative lipid content in perifemoral muscles, and muscle mass in 
the four groups of rats 
Treatment 
 
Liver/body weight  (%) Liver triglyceride (mmol/kg) Muscle lipids (%wet weight) Muscle mass (g) 
Control  2.64 ± 0.34a  23.6 ± 2.0ab  2.14 ± 0.192a     7.4 ± 0.2ab 
Guanethidine  3.20 ± 0.13ab      19.9 ± 1.7a  2.03 ± 0.14a    8.0 ± 0.4a 
Dexamethasone  3.51 ± 0.18b  32.8 ± 5.6ab  1.96 ± .018a     7.2 ± 0.4ab 
Guan + Dex  3.72 ± 0.22b     33.5 ± 2.9b   3.32 ± 0.44b    6.2 ± 0.4b 
ANOVA (F)        
Guanethidine 3.6  0.1  6.4*  0.4 
Dexamethasone  12** 7.2* 5.0* 7.9* 
Guan X Dex  0.8  0.3  8.8**  4.6* 
*P < 0.05; 
** P < 0.01 by two-way ANOVA. Within a column, values bearing the same letter are not significantly different by one-way ANOVA.  
4.  DISCUSSION  
Guanethidine administration in adult rats three 
times per week for three weeks resulted in low NE 
concentration in four internal organs (Table 1), as 
measured more than two months after having 
concluded the treatment, confirming that this 
protocol is as effective as the neonatal administration 
[19]. The effects in heart and liver were similar to 
those obtained in a previous experiment in which Gu 
was injected into neonatal rats [15].  
Sympathectomy alone had weak effects on food 
intake and body-weight gain (Table 2), confirming the 
results of other authors [11-14]. The Gu group of rats 
showed better glucose tolerance. Glucose tolerance 
depends on peripheral insulin resistance, hepatic 
insulin resistance, and/or glucose-induced pancreatic 
insulin secretion. Sympathetic activation stimulates 
peripheral glucose uptake by a β3-adrenergic effect 
[20-22] but inhibits insulin secretion, an α2-adrenergic 
effect [22]. Insulin was not measured in this work but 
the better glucose tolerance of the sympathectomized 
rats might be attributed to the practical lack of NE in 
the pancreas, which should permit the release of 
more insulin under the stimulus of glucose. 
Chronic sucrose intake induces chronic 
hyperinsulinemia [24-26]. This results in a stimulation 
of leptin secretion, [26,27] more so in the presence of  
low sympathetic activity, because β3-adrenergic 
action inhibits leptin secretion [26,28,29]. Compared 
with the situation of the control group, 
sympathectomy may have increased leptin 
production resulting in improved glucose uptake and 
lower body-weight gain [30,31]. A relationship 
between these variables is shown by their significant 
linear correlation when the D group was not included 
(see below). 
Generally speaking, dexamethasone was 
administered by various authors in much larger doses 
and for less time. Coderre et al. [24] combined sucrose 
in the drinking water with subcutaneous injection of 
D (0.4 or 1.0 mg/day) for 7 days. The D treatment 
with the lower dose induced body-weight loss, 
hyperglycemia, hyperinsulinemia and 
hypertriglyceridemia. Sucrose affected only the two 
last variables, and the combination of treatments did 
not increase the effects of these large doses of D. 
In the present work, glucose tolerance of the D 
group was the worst and may be easily attributed to 
D-induced insulin resistance [3]. The relationship 
between glycemic AUC and body-weight gain was 
different from the other three groups and, although 
not reaching statistical significance because of the 
data of one rat (see Fig. 2), the slope of the linear 
regression for the other six rats is much steeper, 
suggesting that glycemic AUC increased much more 
for each increase in body weight gain. This shows 
that D-induced insulin resistance is increased 
proportionally more when body weight increases. 
Some interesting results were shown by the 
Gu+D group of rats. The huge reduction of NE 
content induced by sympathectomy in the 4 organs 
was not affected by D administration but food intake 
was significantly lower and body-weight actually 
decreased showing the catabolic action of D is 
probably not due to sympathetic activation. The 
proportional intake of sucrose was significantly 
higher in this group. The differences between these 
variables in D and Gu+D are caused, perhaps 
directly, by the low sympathetic activity in the second 
group. As already discussed, sympathectomy may 
increase leptin production and it is known that 
glucocorticoids stimulate it [32,33]. The difference 
between the two groups could be that, in the D 
group, the inhibitory action of the sympathetic 
system on leptin secretion is present but is lacking in 
the Gu+D group. 
High leptin levels could tentatively explain also 
the preference for sucrose by these rats. Beck et al. 
[34] reported that ghrelin, which stimulates feeding, 
is inversely correlated with plasma leptin and has 
lower plasma levels in the carbohydrate-preferring 
rats. This suggests indirectly that, on the contrary, 
high leptin levels may be associated with 
carbohydrate preference. Another indirect clue is 
given by the article of Velasquez-Mieyer et al. [35] 
reporting that the suppression of insulin secretion in 
obese humans induced, among other effects, a 
decrease in leptin levels and in carbohydrate craving. 
The same Gu+D group of rats showed the best 
glucose tolerance. Because this was the group that 
had lost weight and had supposedly also the highest 
leptin levels, two conditions that improve glucose 
tolerance [29,30] such a result might be expected. The 
statistically significant correlation between body-
weight gain and glucose AUC support this 
interpretation.  Int. J. Biol. Sci. 2006, 2  21
The D-induced increase in relative liver weight 
and liver triglyceride content confirms our previous 
results [2]. Muscle lipids are associated with insulin 
resistance [36,37]. However, the present results show 
that the group Gu+D had the best glucose tolerance 
but the highest lipid content in the perifemoral 
muscles, clearly caused by the combination of the two 
treatments, as shown by the significant interaction 
between their effects. The relatively higher levels of 
fat might be caused by the relatively low level of the 
main component of muscle, the proteins, as shown by 
the low muscle mass in the Gu+D group. The 
proteolytic action of glucocorticoids is well-known 
and, as the catecholamines inhibit proteolysis [38], 
this muscle mass reduction could be caused by a 
potentiation of effects of the two treatments. 
In summary, in adult rats drinking a 10% 
sucrose solution chemical sympathectomy caused by 
guanethidine treatment for 3 weeks reduced 
norepinephrine levels in four organs by more than 
90% and decreased food intake. It also improved 
glucose tolerance, a result that has not been reported 
before. Dexamethasone, besides reducing food intake 
and body-weight gain and increasing liver 
triglyceride content, impaired glucose tolerance. 
When guanethidine-treated animals received 
dexamethasone some novel aspects were seen: an 
increase in drinking the sucrose solution, a negative 
body-weight gain, and a consistently better glucose 
tolerance. This last effect was the only improvement 
shown by combining sympathectomy with 
dexamethasone treatment. In exchange, the negative 
food efficiency suggests that dexamethasone catabolic 
effect is not due to sympathetic activation. 
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